5-氟-2,3-二氢-6-甲氧基-1H-茚-1-酮 | 83802-71-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 5-氟-2,3-二氢-6-甲氧基-1H-茚-1-酮
• 英文名称: 5-fluoro-6-methoxy-2,3-dihydro-1H-inden-1-one
• 英文别名: 5-fluoro-6-methoxy-2,3-dihydroinden-1-one
• CAS: 83802-71-5
• 化学式: C₁₀H₉FO₂
• mdl: MFCD09261202
• 分子量: 180.179
• InChiKey: FFZRFPIFJVKURP-UHFFFAOYSA-N

物化性质

• 熔点：
  148 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  312.0±42.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-氟-2,3-二氢-6-甲氧基-1H-茚-1-酮 在 盐酸 、 氢氧化钾 、 三溴化硼 、 汞 、 锌 作用下， 以 二氯甲烷 、 水 、 甲苯 、 叔丁醇 为溶剂， 反应 11.0h， 生成 5-(4-Bromo-butoxy)-6-fluoro-indan
  参考文献：
  名称：

  Synthesis and antianxiety activity of (.omega.-piperazinylalkoxy)indan derivatives

  摘要：

  A series of (omega-piperazinylalkoxy)indan derivatives has been synthesized and screened for potential antianxiety activities. The effect of structural modification of these molecules on activities has been systemically examined. Antianxiety activity was displayed by 5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (2), 5-[3-[4-(4-fluorophenyl)-1-piperazinyl]-propoxy]indan (8), 6-fluoro-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (33), and 6-methyl-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (42), as determined in antifighting and anti-morphine tests. These derivatives in antianxiety tests were equipotent or more potent than chlordiazepoxide with less muscle-relaxant effect. They also showed weak neuroleptic-like action.

  DOI：

  10.1021/jm00356a024
• 作为产物：
  描述：

  3-氟-4-甲氧基苯甲醛 生成 5-氟-2,3-二氢-6-甲氧基-1H-茚-1-酮
  参考文献：
  名称：

  Melatonergic indanyl piperazines

  摘要：

  某些吲哚基哌嗪类化合物可作为褪黑激素受体激动剂，并可用于治疗各种中枢神经系统疾病。它们在治疗睡眠障碍和其他与昼夜节律相关的疾病方面非常有用。

  公开号：

  US05780470A1

文献信息

• Tricyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06034239A1

  公开（公告）日：2000-03-07

  A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.

  该化合物的结构式为：##STR1## 其中R.sup.1是可选择取代的碳氢化合物、氨基或杂环基团；R.sup.2是H或可选择取代的碳氢基团；R.sup.3是H或可选择取代的碳氢或杂环基团；X是CHR.sup.4、NR.sup.4、O或S，其中R.sup.4是H或可选择取代的碳氢基团；Y是C、CH或N；环A是可选择取代的5-至7-成员环；环B是可选择取代的苯环；m为1至4，或其盐，提供了其制备方法、生产中间体和包含它的药物组合物。
• Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1199304A1

  公开（公告）日：2002-04-24

  A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

  具有以下一般式的化合物： 其中R1是可选择取代的碳氢化合物、氨基或杂环基团；R2是H或可选择取代的碳氢基团；R3是H或可选择取代的碳氢基团或杂环基团；X是CHR4、NR4、O或S，其中R4是H或可选择取代的碳氢基团；R5是H、卤素原子、C1-6烷基基团、C1-6烷氧基团、羟基、硝基、氰基或氨基，其中C1-6烷基基团、C1-6烷氧基团和氨基可能被1至5个取代基取代，Y是C或N；环B是可选择取代的苯环；m = 1至4，n = 0至2；L代表离去基团，如卤素原子、烷基磺酰基团、烷基磺酰氧基团和芳基磺酰氧基团；或其盐。
• Benzocycloalkene compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05922771A1

  公开（公告）日：1999-07-13

  A compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 independently represent H or an optionally substituted hydrocarbon group; R.sup.3 represents an optionally substituted hydrocarbon group; R.sup.4 represents H or a hydrocarbon group; ring A represents a substituted benzene ring; X represents a C.sub.2-4 alkylene group etc.; and Y represents a bond or a lower alkylene group, or salts thereof is useful as prophylactic or therapeutic agents of diseases related with melatonin activity.

  式##STR1##中的化合物，其中R.sup.1和R.sup.2分别代表H或一个可选择取代的碳氢基团；R.sup.3代表一个可选择取代的碳氢基团；R.sup.4代表H或一个碳氢基团；环A代表一个取代的苯环；X代表一个C.sub.2-4烷基基团等；Y代表键或一个较低的烷基基团，或其盐，可用作与褪黑激素活性相关的疾病的预防或治疗剂。
• Melatonergic indanyl piperazines
  申请人：Bristol-Myers Squibb Company

  公开号：US05780470A1

  公开（公告）日：1998-07-14

  Certain indanyl piperazines are useful as melatonergic agents and can treat various CNS disorders. They are use useful in treating sleep disorders and other conditions related to circadian rhythms.

  某些吲哚基哌嗪类化合物可作为褪黑激素受体激动剂，并可用于治疗各种中枢神经系统疾病。它们在治疗睡眠障碍和其他与昼夜节律相关的疾病方面非常有用。
• [EN] SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS<br/>[FR] COMPOSÉS DE SULFONIMIDAMIDE EN TANT QUE MODULATEURS DE NLRP3
  申请人：GENENTECH INC

  公开号：WO2021150574A1

  公开（公告）日：2021-07-29

  Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

  本文描述了式(I)、式(I-A)和式(I-B)的化合物，以及它们的溶剂化物、互变异构体和上述化合物的药用可接受盐，此外，本文还描述了使用这些化合物抑制NLRP3的方法，以及用于治疗NLRP3依赖性疾病的方法和组合物。